Valuation: AstraZeneca PLC

Market Cap 255B 224B 211B 193B 361B 24,463B 363B 2,536B 983B 12,450B 957B 936B 40,514B P/E 2026 *
20.9x
P/E 2027 * 18.2x
Enterprise Value 275B 241B 228B 208B 388B 26,353B 391B 2,732B 1,059B 13,412B 1,031B 1,008B 43,645B EV / Sales 2026 *
4.35x
EV / Sales 2027 * 3.98x
Free-Float
96.62%
Yield 2026 *
2.04%
Yield 2027 * 2.16%
1 day+1.07%
Current month+77.38%
Current year+79.01%
Current year 89.04
Extreme 89.04
166.25
1 year 72.9
Extreme 72.895
166.25
3 years 60.47
Extreme 60.47
166.25
5 years 52.65
Extreme 52.65
166.25
10 years 25.55
Extreme 25.55
166.25
Manager TitleAgeSince
Chief Executive Officer 66 30/09/2012
Director of Finance/CFO 52 31/07/2021
Compliance Officer - 31/12/2022
Director TitleAgeSince
Director/Board Member 70 05/04/1999
Director/Board Member 66 30/09/2012
Director/Board Member 65 26/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%+0.27% - - 256B
+2.68%+2.56%+59.32%+114.00% 1,026B
+0.56%+0.17%+53.19%+68.90% 649B
+0.02%+0.42%+20.51%+71.43% 468B
+0.06%+0.25%+37.03%+45.71% 352B
+1.16%+4.10%+21.99%+29.39% 271B
-0.24%+2.18%+10.14%+12.26% 256B
-0.01%+6.91%+45.42%+52.15% 220B
-1.11%-0.80%+31.69%+100.04% 188B
+0.30%-7.19%-32.43%-60.56% 170B
Average +0.61%+1.26%+27.43%+48.15% 399.9B
Weighted average by Cap. +1.18%+1.26%+38.06%+67.31%

Financials

2026 *2027 *
Net sales 63.17B 55.56B 52.38B 47.79B 89.37B 6,063B 90.06B 629B 244B 3,086B 237B 232B 10,042B 67.01B 58.94B 55.57B 50.7B 94.81B 6,433B 95.54B 667B 258B 3,274B 252B 246B 10,653B
Net income 12.04B 10.59B 9.99B 9.11B 17.04B 1,156B 17.17B 120B 46.44B 588B 45.22B 44.24B 1,915B 13.77B 12.11B 11.42B 10.42B 19.49B 1,322B 19.64B 137B 53.11B 673B 51.71B 50.59B 2,190B
Net Debt 19.69B 17.32B 16.33B 14.9B 27.86B 1,891B 28.08B 196B 75.94B 962B 73.94B 72.34B 3,131B 11.93B 10.49B 9.89B 9.03B 16.88B 1,145B 17.01B 119B 46B 583B 44.8B 43.82B 1,897B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
24/09/26 US$164.56 +0.75% 3,019,764
23/09/26 US$163.33 -2.99% 2,361,340
22/09/26 US$168.37 +0.16% 2,306,261
21/09/26 US$168.10 +1.22% 2,937,798
18/09/26 US$166.08 -0.04% 3,060,378
Trader
Investor
Global
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise